Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 27, 2015
- Accepted in final form December 8, 2015
- First Published January 27, 2016.
Author Disclosures
- Rohit Bakshi, MD,
- Ada Yeste, PhD,
- Bonny Patel, MSc,
- Shahamat Tauhid, MD,
- Subhash Tummala, MD,
- Roya Rahbari, PhD,
- Renxin Chu, MD,
- Keren Regev, MD,
- Pia Kivisäkk, MD, PhD,
- Howard L. Weiner, MD and
- Francisco J. Quintana, PhD
- Rohit Bakshi, MD,
NONE
NONE
NONE
Dr. Bakshi serves as Editor-in-Chief of the Journal of Neuroimaging
NONE
NONE
NONE
Dr. Bakshi has received consulting fees from AbbVie, Alkermes, Biogen, Novartis, and Questcor
NONE
NONE
NONE
Dr. Bakshi has received research support from Biogen, EMD-Serono, Novartis, Sanofi-Genzyme, and Teva.
NONE
NONE
NONE
Dr. Bakshi's spouse holds stock in Biogen, Inc.
NONE
NONE
Dr. Bakshi's spouse holds stock in Biogen, Inc.
Dr. Bakshi's spouse holds stock in Biogen, Inc.
NONE
- Ada Yeste, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bonny Patel, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shahamat Tauhid, MD,
NONE
NONE
NONE
Journal of Neuroimaging, Managing Editor, 2015-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Subhash Tummala, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roya Rahbari, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Renxin Chu, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Keren Regev, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pia Kivisäkk, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from EMD Serono.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Howard L. Weiner, MD and
served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis
NONE
NONE
NONE
NONE
NONE
NONE
Therapix Biogen Novartis Serono Teva Sanofi
NONE
NONE
NONE
EMD Serono
NIH
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Francisco J. Quintana, PhD
NONE
NONE
NONE
2012 Editorial Board MemberSystems Biomedicine 2012 Editorial Board Member Inmunologia (Spain) 2013- Associate Editor Immunology (UK) 2013-Senior Editorial Board MemberAmerican Journal of Clinical and Experimental Immunology 2014- Advisory Board Member Seminars in Immunopathology
NONE
NONE
NONE
Teva, Blueprint Medicines
NONE
NONE
NONE
1. EMD-Serono 2. Sanofi 3. Novartis 4. Teva
(1) NIH, R00 AI075285-01A2, Role PI, 2010-2012, (2) NIH,R01 AI093903-01, Role PI, 2011?2016, (3) NIH,K99AI075285-01A2, Role PI, 2009-2010
(1) Harvard Medical School, Diversity and Community Partnership Faculty Fellowship, Role PI, 2010-2012, (2) BADERC, Pilot and Feasibility Award (Quintana), Role PI, 2010-2012
(1) NMSS, RG4111A1/1, Role PI, 2009-2012, (2) NMSS, RG4048A11, Role Research Associate, 2008-2011
NONE
NONE
NONE
NONE
NONE
NONE
- From the Partners Multiple Sclerosis Center (R.B., S. Tauhid, S. Tummala, R.C., H.L.W.) and Ann Romney Center for Neurologic Diseases (R.B., A.Y., B.P., R.R., K.R., P.K., H.L.W., F.J.Q.), Neurology (R.B., A.Y., B.P., S. Tauhid, S. Tummala, R.R., R.C., K.R., P.K., H.L.W., F.J.Q.) and Radiology (R.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Correspondence to Dr. Quintana: fquintana{at}rics.bwh.harvard.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.